Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11012033rdf:typepubmed:Citationlld:pubmed
pubmed-article:11012033lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C0016016lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C0282639lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C0313532lld:lifeskim
pubmed-article:11012033lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:11012033pubmed:issue19lld:pubmed
pubmed-article:11012033pubmed:dateCreated2001-1-3lld:pubmed
pubmed-article:11012033pubmed:abstractTexttrans-4-Aminomethylcyclohexanecarbonyl-Tyr(O-Pic)-octylamide (YO-2) inhibited plasmin (PL) selectively, while trans-4-aminomethylcyclohexanecarbonyl-Phe-4-carboxymethylanili de (YO-1) inhibited plasma kallikrein (PK). YO-2 induced apoptosis of M1 (melanoma) cell line and HT29 colon carcinoma cells during 24 h through activation of caspase-3, while YO-1 did not affect either cell line even during 48 h.lld:pubmed
pubmed-article:11012033pubmed:languageenglld:pubmed
pubmed-article:11012033pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:citationSubsetIMlld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11012033pubmed:statusMEDLINElld:pubmed
pubmed-article:11012033pubmed:monthOctlld:pubmed
pubmed-article:11012033pubmed:issn0960-894Xlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:OkadaYYlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:OkamotoSSlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:TadaMMlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:SzendeBBlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:OkamotoUUlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:TsudaYYlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:KerrLLlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:Hijikata-Okun...lld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:WanakaKKlld:pubmed
pubmed-article:11012033pubmed:authorpubmed-author:BokonyiGGlld:pubmed
pubmed-article:11012033pubmed:issnTypePrintlld:pubmed
pubmed-article:11012033pubmed:day2lld:pubmed
pubmed-article:11012033pubmed:volume10lld:pubmed
pubmed-article:11012033pubmed:ownerNLMlld:pubmed
pubmed-article:11012033pubmed:authorsCompleteYlld:pubmed
pubmed-article:11012033pubmed:pagination2217-21lld:pubmed
pubmed-article:11012033pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:meshHeadingpubmed-meshheading:11012033...lld:pubmed
pubmed-article:11012033pubmed:year2000lld:pubmed
pubmed-article:11012033pubmed:articleTitleDevelopment of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines.lld:pubmed
pubmed-article:11012033pubmed:affiliationFaculty of Pharmaceutical Sciences, Kobe Gakuin University, Japan. okada@pharm.kobegakuin.ac.jplld:pubmed
pubmed-article:11012033pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:11012033lld:chembl